Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
JAMA Network Open
|
February 14, 2025
Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma: A Children's Oncology Group Report
Puja J Umaretiya, Arlene Naranjo, Fan F Zhang, et al.
Clinical Trials (London, England)
|
October 25, 2023
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1
Liny John, Gurbani Singh, Eva Dombi, et al.
Pediatric Blood & Cancer
|
May 24, 2021
A safety and feasibility trial of <sup>131</sup> I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study
Brian D Weiss, Gregory Yanik, Arlene Naranjo, et al.
Neuro-Oncology
|
April 28, 2023
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas
Andrea M Gross, Eva Dombi, Pamela L Wolters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Brian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2017
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Araz Marachelian, Judith G Villablanca, Cathy W Liu, et al.
Neuro-Oncology
|
April 25, 2022
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity
Andrea M Gross, Brittany Glassberg, Pamela L Wolters, et al.
Cancer
|
February 11, 2025
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
Steven G DuBois, Chitose Ogawa, Lucas Moreno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2022
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor
Benjamin J Lerman, Yimei Li, Cecilia Carlowicz, et al.
Transplantation and Cellular Therapy
|
April 6, 2021
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1
M Meaghan Granger, Arlene Naranjo, Rochelle Bagatell, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
JAMA Network Open
|
February 14, 2025
Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma: A Children's Oncology Group Report
Puja J Umaretiya, Arlene Naranjo, Fan F Zhang, et al.
Clinical Trials (London, England)
|
October 25, 2023
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1
Liny John, Gurbani Singh, Eva Dombi, et al.
Pediatric Blood & Cancer
|
May 24, 2021
A safety and feasibility trial of <sup>131</sup> I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study
Brian D Weiss, Gregory Yanik, Arlene Naranjo, et al.
Neuro-Oncology
|
April 28, 2023
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas
Andrea M Gross, Eva Dombi, Pamela L Wolters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Brian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2017
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Araz Marachelian, Judith G Villablanca, Cathy W Liu, et al.
Neuro-Oncology
|
April 25, 2022
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity
Andrea M Gross, Brittany Glassberg, Pamela L Wolters, et al.
Cancer
|
February 11, 2025
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
Steven G DuBois, Chitose Ogawa, Lucas Moreno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2022
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor
Benjamin J Lerman, Yimei Li, Cecilia Carlowicz, et al.
Transplantation and Cellular Therapy
|
April 6, 2021
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1
M Meaghan Granger, Arlene Naranjo, Rochelle Bagatell, et al.
Page
of 4